---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-005418"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2022-04-14T23:59:59+00:00"
generated_at: "2026-06-26T07:24:32.717421+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine appoints Gilmore O'Neill as President and CEO, effective June 1, 2022

## Summary
- Gilmore O'Neill, former EVP of R&D at Sarepta, succeeds James Mullen as CEO; Mullen becomes Executive Chair.
- O'Neill receives $625K base salary, 60% target bonus, and equity valued at ~$11M (options + RSUs + performance RSUs).
- Mullen's base remains $655K through Dec 2022, then drops to $327.5K for part-time Executive Chair from Jan 2023.
- O'Neill appointed to Board as class II director until 2024 annual meeting.

## SEC filing metadata
- accession: 0001558370-22-005418
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2022-04-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000155837022005418/0001558370-22-005418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000155837022005418/edit-20220412x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-005418
- JSON: https://secwatch.observer/filing/0001558370-22-005418.json
- Plain text: https://secwatch.observer/filing/0001558370-22-005418.txt

## Key facts
- Executive change
  Gilmore O'Neill was appointed as President and Chief Executive Officer at Editas Medicine, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On April 12, 2022, Editas Medicine, Inc. (the “Company”) appointed Gilmore O’Neill, M.B., M.M.Sc. as President and Chief Executive Officer of the Company, succeeding James C. Mullen as President and Chief Executive Officer of the Company, effective as of June 1, 2022 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837022005418/0001558370-22-005418-index.htm
- Executive change
  Gilmore O'Neill was appointed as director at Editas Medicine, Inc..
  - Action: appointed
  - Role: director
  source text: Also on April 12, 2022, the Board, upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Dr. O’Neill as a director, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837022005418/0001558370-22-005418-index.htm
- Executive change
  James C. Mullen changed role as Executive Chair at Editas Medicine, Inc..
  - Action: will continue to serve as
  - Role: Executive Chair
  source text: Mr. Mullen will continue to serve as Executive Chair of the Company’s Board of Directors (the “Board”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837022005418/0001558370-22-005418-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.